Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WINGMEN: Xentuzumab in Prostate Cancer
NCT05110495Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Dec 2021
- Primary completion
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of xentuzumab in prostate cancer (PCa), sponsored by University of Oxford. Primary endpoints: Percentage Change of Phospho-IGF-1R Positive Tumour Cells Following Treatment With Xentuzumab and Percentage Change of Phospho-S6 Positive Tumour Cells Following Treatment With Xentuzumab. Started Dec 2021; status: completed.
02
Drugs
xentuzumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05110495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05110495.